Enanta Pharmaceuticals (NASDAQ:ENTA) Given New $20.00 Price Target at Robert W. Baird

Enanta Pharmaceuticals (NASDAQ:ENTA) had its price target lowered by Robert W. Baird from $26.00 to $20.00 in a research note published on Tuesday,Benzinga reports. The brokerage currently has an outperform rating on the biotechnology company’s stock.

Other analysts have also recently issued research reports about the company. JMP Securities reaffirmed a “market outperform” rating and set a $21.00 target price (down previously from $22.00) on shares of Enanta Pharmaceuticals in a research report on Tuesday. HC Wainwright reissued a “buy” rating and issued a $27.00 price objective on shares of Enanta Pharmaceuticals in a research report on Thursday, October 10th. JPMorgan Chase & Co. lowered their price objective on Enanta Pharmaceuticals from $11.00 to $10.00 and set an “underweight” rating for the company in a research report on Tuesday, August 6th. Finally, Evercore ISI raised Enanta Pharmaceuticals to a “strong-buy” rating in a research report on Tuesday, August 6th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, three have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $19.50.

Enanta Pharmaceuticals Trading Down 5.0 %

Shares of NASDAQ ENTA opened at $8.56 on Tuesday. The stock has a market capitalization of $181.38 million, a PE ratio of -1.57 and a beta of 0.56. The stock’s fifty day simple moving average is $10.97 and its two-hundred day simple moving average is $12.33. Enanta Pharmaceuticals has a 12-month low of $8.00 and a 12-month high of $17.80.

Institutional Investors Weigh In On Enanta Pharmaceuticals

Several large investors have recently bought and sold shares of ENTA. State Board of Administration of Florida Retirement System purchased a new stake in shares of Enanta Pharmaceuticals in the first quarter valued at approximately $118,000. Vanguard Group Inc. grew its position in shares of Enanta Pharmaceuticals by 7.5% in the first quarter. Vanguard Group Inc. now owns 1,928,078 shares of the biotechnology company’s stock valued at $33,664,000 after purchasing an additional 134,292 shares in the last quarter. Virtu Financial LLC purchased a new stake in shares of Enanta Pharmaceuticals in the first quarter valued at approximately $191,000. Farallon Capital Management LLC grew its position in shares of Enanta Pharmaceuticals by 3.5% in the first quarter. Farallon Capital Management LLC now owns 2,095,000 shares of the biotechnology company’s stock valued at $36,579,000 after purchasing an additional 70,000 shares in the last quarter. Finally, Bank of New York Mellon Corp grew its position in shares of Enanta Pharmaceuticals by 13.3% in the second quarter. Bank of New York Mellon Corp now owns 73,841 shares of the biotechnology company’s stock valued at $958,000 after purchasing an additional 8,645 shares in the last quarter. 94.99% of the stock is currently owned by hedge funds and other institutional investors.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.